{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:19:08Z","timestamp":1775870348157,"version":"3.50.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years. The role of chemoimmunotherapy has declined significantly for patients with CLL. Fludarabine, cyclophosphamide, rituximab chemotherapy remains the standard frontline therapy for young fit patients with CLL, especially if IGHV mutated. For older adults, ibrutinib has been shown to be superior to chlorambucil. Hence, the role of chlorambucil monotherapy in the current era in the management of CLL is limited. The combination of chlorambucil and obinutuzumab is an alternative option for patients with comorbidities. For patients with del(17p), ibrutinib has become the standard treatment in the frontline setting. Several phase 3 trials with novel targeted agents, either as monotherapy or in combination, are either ongoing or have completed accrual. The results of many of these trials are expected in the next 1 to 2 years, and they will further help refine the frontline treatment strategy.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.242","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:59Z","timestamp":1555438439000},"page":"242-247","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Selecting Frontline Therapy for CLL in 2018"],"prefix":"10.1182","volume":"2018","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2019111520570515200_B1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.blre.2015.12.002","article-title":"Targeted therapies for CLL: practical issues with the changing treatment paradigm","volume":"30","author":"Jain","year":"2016","journal-title":"Blood Rev"},{"issue":"5","key":"2019111520570515200_B2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2010.32.3865","article-title":"Update on therapy of chronic lymphocytic leukemia","volume":"29","author":"Gribben","year":"2011","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111520570515200_B3","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111520570515200_B4","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111520570515200_B5","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9747","key":"2019111520570515200_B6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"2019111520570515200_B7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111520570515200_B8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2015-04-585067","article-title":"Initial treatment of CLL: integrating biology and functional status","volume":"126","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2019111520570515200_B9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"2019111520570515200_B10","article-title":"Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies [published online ahead of print 17 April 2018]","author":"Thompson","journal-title":"Leukemia"},{"issue":"9","key":"2019111520570515200_B11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111520570515200_B12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2019111520570515200_B13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"16","key":"2019111520570515200_B14","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111520570515200_B15","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2017.72.6810","article-title":"Chemoimmunotherapy is not dead yet in chronic lymphocytic leukemia","volume":"35","author":"Brown","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111520570515200_B16","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2019111520570515200_B17","first-page":"495","article-title":"Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for first-line treatment of patients with CLL with mutated IGHV and without TP53 aberrations","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2019111520570515200_B18","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"key":"2019111520570515200_B19","first-page":"496","article-title":"A multicenter, phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019111520570515200_B20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111520570515200_B21","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"2019111520570515200_B22","author":"Goede","year":"2018"},{"issue":"9980","key":"2019111520570515200_B23","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2019111520570515200_B24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3324\/haematol.2017.170480","article-title":"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2019111520570515200_B25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111520570515200_B26","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2019111520570515200_B27","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2019111520570515200_B28","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2014.104661","article-title":"Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion","volume":"99","author":"Strati","year":"2014","journal-title":"Haematologica"},{"issue":"25","key":"2019111520570515200_B29","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111520570515200_B30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.V128.22.234.234","article-title":"Updated efficacy and safety from the phase 3 Resonate- 2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia\/small lymphocytic leukemia","volume":"128","author":"Barr","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111520570515200_B31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"2019111520570515200_B32","author":"Michallet","year":"2018"},{"key":"2019111520570515200_B33","first-page":"432","article-title":"Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-naive patients with chronic lymphocytic leukemia: the phase 1b\/2 ACE-CL-003 study","volume":"130","author":"Woyach","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520570515200_B34","first-page":"427","article-title":"Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL)","volume":"130","author":"Burger","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2019111520570515200_B35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111520570515200_B36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"2019111520570515200_B37","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"2019111520570515200_B38","first-page":"430","article-title":"Safety, efficacy and MRD negativity of a combination of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia - results from a phase 1b study (GP28331)","volume":"130","author":"Flinn","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2019111520570515200_B39","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"key":"2019111520570515200_B40","first-page":"429","article-title":"Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed\/refractory CLL: a phase II trial","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"2019111520570515200_B41","first-page":"431","article-title":"Initial results of the phase 2 treatment naive cohort in a phase 1b\/2 study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia","volume":"130","author":"Rogers","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111520570515200_B42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2019111520570515200_B43","first-page":"4037","article-title":"an integrated safety analysis of the next generation PI3K\u03b4 inhibitor umbralisib (TGR-1202) in patients with relapsed\/refractory lymphoid malignancies","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/242\/1253452\/hem01833.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/242\/1253452\/hem01833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:39:45Z","timestamp":1573861185000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/242\/277585\/Selecting-Frontline-Therapy-for-CLL-in-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.242","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}